Aceto Strikes Deal To Offload Rising For Just US$15m
Executive Summary
Aceto has struck a deal to sell its Rising Pharmaceuticals unit and related businesses to Shore Suven Pharma for US$15 million. The agreement comes shortly after Aceto agreed to divest its chemicals business assets for US$338 million after filing Chapter 11 bankruptcy petitions in the US.
You may also be interested in...
Rising Bags Private Equity Investment As Parent Suven Pharma Sells Stake
Executive Summary: Through a transaction valued at approximately $56.4m, the private equity giant H.I.G. Capital has acquired Suven Pharma’s 25% stake in Rising Pharma Holdings.
Rogers Becomes Aceto’s President
Steven Rogers has become president of ailing US firm Aceto, in the wake of William Kennally’s termination as president and CEO. Meanwhile, the firm’s chief financial officer has also stepped down.
Aceto 'No Longer Requires' CEO Kennally
Aceto has terminated William Kennally’s tenure as president and CEO of the struggling US firm, following deals struck to divest its Rising Pharmaceuticals generics business and chemicals unit as part of bankruptcy proceedings. Meanwhile, the Nasdaq listing has confirmed that Aceto will be delisted in mid-June.